A185 Abstracts processes and decisions. The health economics and health policy literature was reviewed for commentaries and case studies of particular decisions. Where decisions had been made by different bodies on the same technology those were reviewed for consistency. Parallels were drawn with methods of regulating market access in other European countries. RESULTS: NICE procedures were the most thorough but could not be applied early or to all technologies because of their resource-intensive nature. Methodological expectations for company submissions were similar between organisations, but the degree of independent review varied with the annual number of technologies assessed. In most cases, NICE and SMC decisions on the same drug were consistent. SMC most resembled equivalent systems in other European countries by evaluating drugs at launch. AWMSG was most concerned with budget impact. CONCLUSIONS: Most differences between the organisations could be explained by their differing objectives, scope of activities and timing of their intervention. The SMC was more concerned with timely and comprehensive coverage of all drugs, reflecting its closer links to NHS. NICE was only beginning to address implementation. Properly co-coordinated, the sequence of evaluations could follow a logical development of evidence quality over time, with minimal redundant work on company submissions. Without such co-ordination a waste of valuable time and resources is likely. MedPAC report recommended payment for handling costs of Part B specified outpatient drugs based on submitted charges, reduced to costs. This study explores policy implications of MedPAC recommendations concerning potential OPPS pharmacy handling cost payment methodology. METHODS: Various methods of recording charges for pharmacy services were collected from a hospital survey of systems (n = 399) and categorized. Past CMS and MedPAC discussions of pharmacy costs and charges were identified and accumulated in an indexed database. Findings from the hospital sources and the governmental sources were compared and underlying assumptions examined with a view toward predicting 2006 CMS approaches to determining hospital pharmacy handling cost payment. RESULTS: The hospital survey revealed significant variation in whether hospital pharmacy department drug charges recognize overhead such as handling costs. Forty-three percent of survey respondents did include such a charge. Types of charges reported were for dispensing (35%), compounding (25%), a combination of dispensing and compounding (23%) and all other (17%). When entries in the indexed database of CMS and MedPAC discussions of pharmacy costs and charges were compared to the hospital responses about actual departmental cost and charge methods currently in use, analyses revealed a significant differential between methods reported by hospital respondents (including charge compression) and methods discussed in published CMS and MedPAC sources. CONCLUSIONS: Future payment rates for hospital pharmacy handling costs will likely be derived from hospital submitted charges, per the MedPAC recommendation. If the payment methodology does not take existing variations of recording pharmacy costs and charges into account, the resulting method will be significantly flawed and hospital providers may find they are underpaid for pharmacy handling costs in 2006.
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PHP15 THE CONSUMPTION OF DRUGS FINANCED BY THE SPANISH NATIONAL HEALTH SYSTEM AND THE IMPACT OF PHARMACOVIGILANT ACTIONS
Gaspar MD, Modamio P, Lastra CF, Marino EL University of Barcelona, Barcelona, Spain OBJECTIVES: The Spanish Agency of Medicines and Health care Products (SAMHP) makes regulatory decisions concerning pharmacovigilance. Here, we analyse the impact of actions related to safety adopted by the SAMHP on drug consumption financed by the Spanish National Health System (NHS), over the period [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] . METHODS: A retrospective analysis of the consumption was made, selecting drugs which were eventually withdrawn from the market. Consumption data was provided by the Ministry of Health and Consume (MHC) database and expressed as number of prescriptions. Drugs selected were classified according to type of Adverse Drug Reaction (ADR), Anatomic Therapeutic-Chemical Classification (ATC) and degree of therapeutic innovation at the moment of authorisation, according to the MHC. RESULTS: Fourteen drugs were selected for the purpose of this study, and none of these were categorised as "an exceptional therapeutic novelty". The most common ADRs concerned severe liver (7/14) or heart (5/7) toxicity. At least 8 of the 14 drugs were associated with one safety action before being withdrawn. This was either a product labeling modification (astemizole, droxicam, nimesulide, nefazodone, cerivastatine, trovafloxacine, and rofecoxib) or classification as hospitalary diagnostic (cisapride). Rofecoxib was the only one with two actions. A high level of consumption and in a very short time from authorisation until the first safety action (between one to three years) was found in nimesulide, cerivastatine and rofecoxib. In the rest of the drugs, the only action was the withdrawn. This happened after one year post-authorisation (tolcapone, sertindol, and grepafloxacine) or in the case of ebrotidine, two years. CONCLUSIONS: The drugs withdrawn after one or two years from their authorisation would seem reasonable not have been financed by NHS. In all drugs, the first safety action resulted in a significant decrease in consumption. In some of these cases, manufacturers requested to SAMHP drug to be withdrawn.
PHP16 ESTIMATING THE COST SAVINGS AND RATIONAL USE EFFECTS OF IMPLEMENTING AN ESSENTIAL MEDICINES LIST
Hamidi S
Tulane University, New Orleans, LA, USA; 2 Jackson State University, Jackson, MS, USA OBJECTIVES: To determine the effects of implementing essential medicines list on rational use of medicines and medicine cost savings in the public sector of West Bank, Palestine. METHODS: The effect of EML on medicine expenditure was divided into two separate components: the effect of EML on quantities used, and the effect on medicine prices. The quantities of 76 medicine groups were used as the dependent variable with real GDP per capita, EML dummy, hospital dummy, time, and percent of insured population, as independent variables. Another set of regressions were defined with real medicine price per defined daily dose as dependent variable and real GDP per capita, EML, and percent insured as independent variables. A sample of prescriptions was also analyzed to measure the indices of rational medicine use. The indicators of rational use of medicines were assumed to be a function of EML, and 16 health center dummy variables. RESULTS: Expenditures on medicines declined due to negative impact of EML on quantities of medicines utilized per capita as well as on real prices. The quantities declined on average by 1.7 DDDs per capita per year. The medicine price reduced on average by about US $0.0013 per defined daily dose. The real cost saved for the years 2000 to 2003 was about US $ 5.9 million. The EML was effective in shifting all prescribing indicators towards the standard values. CONCLUSIONS: The PMOH should allocate more resources for pharmaceutical budget in the future. The EML was successful in containing medicine cost, and careful review and update of EML should further increase the savings. The development and implementation of antibiotic medicine policy is an urgent need. Introduction of treatment protocols for the most common diseases, and continuous education on rational medicine use for medical staff is required. Nordic School of Public Health, Göteborg, Sweden OBJECTIVE: Mandatory generic substitution of prescribed drugs aiming to moderate the cost increase of pharmaceuticals within the pharmaceutical benefits scheme, PBS, was introduced in October 2002. The study aims to investigate if the introduction of generic substitution had an impact on the development of drugs costs in Sweden for prescribed drugs within PBS and in total. METHODS: Data on the sales of pharmaceuticals to each county council and to the country in total was obtained. Data comprised both total sales (prescriptions, hospitals sales and over the counter sales) and sales of prescribed drugs within the PBS was used for the period January 2000 to May 2005. Expenditure data was expressed as retail prices excluding VAT per 1000 inhabitants in Swedish krona (SEK). Interrupted time series analysis was used to investigate effects related to generic substitution. RESULTS: The county councils' total cost for pharmaceuticals increased from 230 SEK/inhabitants in January 2000 to 280 SEK/inhabitant in May 2005. The county councils' average monthly costs for PBS pharmaceuticals lay in three segments one had a constant cost of ~40 SEK/inhabitant over the study period, the second segment increased from ~140 SEK/inhabitant in 2000 to ~170 SEK/inhabitant in late 2002 where it stabilized and the third segment ~190 SEK/inhabitant in 2000 and increased tõ 210 SEK/inhabitants in late 2002 and after that it was constant. Generic substitution was associated with reduced the slope of increase of costs for drugs within the PBS for the whole country and several of the county councils according to preliminary analyses. This was also seen for several of the county councils' total costs immediately after the introduction of generic substitution. CONCLUSIONS: Preliminary analyses show that generic substitution had an impact in the pace of increase of pharmaceutical expenditures.
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